← Back to Calendar

Cogent Biosciences Q4 2025 Earnings

Cogent Biosciences · $COGT

Standard Review Earnings

PDUFA Date

February 25, 2026

Time Remaining

27d ago

Review Type

Standard (10 mo)

Indication

Q4 2025 earnings + bezuclastinib APEX trial update

Key Notes

Q4 2025 earnings reported February 25, 2026. EPS -$0.61 (missed estimate of -$0.51). Net loss Q4 $102.5M. Update on bezuclastinib APEX Phase 2 trial in advanced systemic mastocytosis — data readout expected mid-2026.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar